Equity L/S Analyst | Forensic Accounting | India, Yellowstone Equity

Ankit Agrawal, CFA

I possess investment research experience across asset classes and geographies, acquired at Investcorp (New York) and Howe & Rusling (Rochester). At Investcorp, an alternative asset manager, I was part of an investment team managing >$1bn in discretionary client assets. I was also a member of investment recommendation, monitoring, cross-asset strategy and macro outlook committees that met periodically for investment decisions and top-down views. At Howe & Rusling, a long-only asset manager, I helped cover US large-cap equity investments across sectors for growth and income focused portfolios as well as assisted in managing a US small-cap growth focused equity portfolio. I possess an MBA in finance and corporate accounting from University of Rochester in US, a CFA Charter, and an Engineering degree from Indian Institute of Technology Bombay in India.  

My current focus is L/S equity fundamental research across market cap and sectors with an eye on corporate governance and forensic accounting. I am currently based in India and my current coverage universe is biased towards India.

-------------
Regulatory Disclosure: Note that Ankit Agrawal (Proprietor of Yellowstone Equity) is a SEBI registered Research Analyst (Registration No.: INH000007216). Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Research Analyst Contact Details -
Address: A-602, Titanium Business Park, Makarba, Ahmedabad - 380051 |
Email: services@yellowstoneequity.com |
Mobile: +91-7575817289

Compliance/Grievance Officer -
Name: Ankit Agrawal |
Email: services@yellowstoneequity.com |
Mobile: +91-7575817289
-------------

Equity L/S Analyst | Forensic Accounting | India

Avid Bioservices: Strong Quarterly Performance Led to 25%+ Re-Rating Last Week. More to Go.

Avid Bioservices | Up ~2x in 7 Months - Since We Initiated Coverage; Highest Ever Order Backlog

US Hidden Gems | Avid Bioservices: Transitioning Avidly to Pure-Play Biologics CDMO

Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex

Wuxi Biologics Placement: Another Pre-Lockup Placement but Past Deals Have Done Well

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/avid-bioservices-inc" target="_blank" data-smartkarma-citation="entities:13309:1" rel="noopener">Avid Bioservices Inc (CDMO US)</a> reported strong Q1FY21 (May - Jul) earnings by clocking its largest quarterly profit ever. In line with our projections as highlighted in our initiation note <a href="https://www.smartkarma.com/insights/us-hidden-gems-avid-bioservices-transitioning-avidly-to-pure-play-biologics-cdmo" target="_blank" data-smartkarma-citation="insights:42254" rel="noopener">US Hidden Gems | Avid Bioservices: Transitioning Avidly to Pure-Play Biologics CDMO</a>, Avid's sales, earnings and cost optimization measures have been all moving in the right direction. Below, we provide more details.</p>

Avid Bioservices Inc (CDMO US) reported strong Q1FY21 (May - Jul) earnings by clocking its largest quarterly profit ever. In line with our projections as highlighted in our initiation note US Hidden Gems | Avid Bioservices: Transitioning Avidly to Pure-Play Biologics CDMO, Avid's sales, earnings and cost optimization measures have been all moving in the right direction. Below, we provide more details.

Avid Bioservices: Reports Largest Quarterly Profit Ever; Robust Guidance and Attractive Valuation